255 related articles for article (PubMed ID: 25835510)
1. Improvement of dumping syndrome and oversecretion of glucose-dependent insulinotropic polypeptide following a switch from olanzapine to quetiapine in a patient with schizophrenia.
Watanabe A; Fukui N; Suzuki Y; Motegi T; Igeta H; Tsuneyama N; Someya T
Gen Hosp Psychiatry; 2015; 37(4):372.e5-6. PubMed ID: 25835510
[TBL] [Abstract][Full Text] [Related]
2. A possible difference in the mechanism for postprandial hypoglycemia associated with dumping syndrome between patients with and without type 2 diabetes.
Hamasaki H; Moriyama S; Yanai H
Obes Res Clin Pract; 2015; 9(6):622-4. PubMed ID: 26321136
[TBL] [Abstract][Full Text] [Related]
3. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.
Garman PM; Ried LD; Bengtson MA; Hsu C; McConkey JR
J Am Pharm Assoc (2003); 2007; 47(3):373-8. PubMed ID: 17510032
[TBL] [Abstract][Full Text] [Related]
4. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
5. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
6. Seven-day subcutaneous continuous glucose monitoring demonstrates that treatment with acarbose attenuates late dumping syndrome in a woman with gastrectomy for gastric cancer.
Buscemi S; Mattina A; Genova G; Genova P; Nardi E; Costanzo M
Diabetes Res Clin Pract; 2013 Jan; 99(1):e1-2. PubMed ID: 23146372
[No Abstract] [Full Text] [Related]
7. Utility of continuous glucose monitoring following gastrectomy.
Kubota T; Shoda K; Ushigome E; Kosuga T; Konishi H; Shiozaki A; Kudo M; Arita T; Murayama Y; Morimura R; Ikoma H; Kuriu Y; Nakanishi M; Fujiwara H; Okamoto K; Fukui M; Otsuji E
Gastric Cancer; 2020 Jul; 23(4):699-706. PubMed ID: 31916026
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
9. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
Sacchetti E; Valsecchi P; Parrinello G;
Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
[TBL] [Abstract][Full Text] [Related]
10. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT
Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
[TBL] [Abstract][Full Text] [Related]
11. Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia.
Sirota P; Pannet I; Koren A; Tchernichovsky E
Hum Psychopharmacol; 2006 Jun; 21(4):227-34. PubMed ID: 16783811
[TBL] [Abstract][Full Text] [Related]
12. Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine.
Voruganti LP; Awad AG; Parker G; Forrest C; Usmani Y; Fernando ML; Senthilal S
Schizophr Res; 2007 Nov; 96(1-3):146-55. PubMed ID: 17728106
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of refractory schizophrenia with combined olanzapine and quetiapine in a patient with a prolactin secreting pituitary microadenoma.
Dunkley MJ; Reveley MA
J Psychopharmacol; 2005 Jan; 19(1):97-101. PubMed ID: 15671135
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of beinaglutide in a patient with late dumping syndrome after gastrectomy: A case report.
Ding B; Hu Y; Yuan L; Yan RN; Ma JH
Medicine (Baltimore); 2021 May; 100(21):e26086. PubMed ID: 34032745
[TBL] [Abstract][Full Text] [Related]
15. Resource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a Medicaid population.
Yu AP; Atanasov P; Ben-Hamadi R; Birnbaum H; Stensland MD; Philips G
Value Health; 2009; 12(5):708-15. PubMed ID: 19508658
[TBL] [Abstract][Full Text] [Related]
16. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
[TBL] [Abstract][Full Text] [Related]
17. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia.
Kinon BJ; Liu-Seifert H; Adams DH; Citrome L
J Clin Psychopharmacol; 2006 Dec; 26(6):632-7. PubMed ID: 17110821
[TBL] [Abstract][Full Text] [Related]
18. Olanzapine-Induced Reversible Pellagroid Skin Lesion.
Singh LK; Sahu M; Praharaj SK
Curr Drug Saf; 2015; 10(3):251-3. PubMed ID: 26077832
[TBL] [Abstract][Full Text] [Related]
19. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
István S; Agoston T; Tamás T; Zoltán J
Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
